Loading article...
Loading article...
Stream/Area:
-
Subject:
-
Paper ID:
IJSREM67220
Volume:
10 |
9 |
Sep 2026
Pages:
1-7
Publication Frequency:
Monthly (12 issues per year)
License:International Journal of Scientific Research in Engineering and Management follows the Creative Commons Attribution 4.0 (CC BY 4.0) License, allowing free use and distribution with proper attribution.
Pharmaceutical Technology
AU College of Pharmaceutical Sciences, Andhra University
Pharmaceutical Technology
AU College of Pharmaceutical Sciences, Andhra University
Pharmaceutical Technology
AU College of Pharmaceutical Sciences, Andhra University
Pharmaceutical Technology
AU College of Pharmaceutical Sciences, Andhra University
Brain tumors are considered some of the most critical and difficult cancers to treat because of their rapid growth, intricate location within vital brain structures, and the presence of the blood-brain barrier (BBB), which limits the entry of many therapeutic agents. Even with improvements in diagnostic imaging, neurosurgical techniques, radiation therapy, and chemotherapy, outcomes, especially in aggressive conditions like glioblastoma, remain unsatisfactory. Traditional treatments often struggle with limited drug accumulation at the tumor site, unwanted systemic side effects, and poor penetration across the BBB. Recent progress in nanotechnology has introduced nanorobotics as a novel strategy in neuro-oncology. Nanorobots are engineered microscopic devices designed to move within biological systems, deliver drugs directly to diseased tissues, and assist in diagnostic monitoring. They can be constructed from a range of materials, including biodegradable polymers, metallic components, and DNA-based structures, and may integrate intelligent control systems for guided navigation. By employing both passive accumulation and active targeting mechanisms, these systems improve precision in tumor localization, increase therapeutic payload delivery, and allow controlled drug release triggered by specific biological signals. Some advanced models, such as enzyme-driven or cell-mediated platforms, have shown encouraging ability to traverse the BBB and penetrate deeply into tumor tissue. Beyond brain tumors, nanorobotic technologies are being explored for applications in infectious diseases, cardiovascular conditions, kidney disorders, and inherited illnesses. Although issues related to safety, large-scale production, regulatory approval, and ethical considerations must be carefully addressed, nanorobotics holds considerable promise as a future tool for highly targeted and personalized treatment in brain tumor management.
KEYWORDS
Brain tumors remain difficult to manage because early detection is often limited, drug delivery across the blood–brain barrier is restricted, and recurrence is common. Although surgery, radiotherapy, and chemotherapy are fundamental components of care, survival rates—particularly in highly aggressive tumors such as glioblastoma—are still unsatisfactory. Nanorobot-based technologies present a promising alternative by integrating targeted movement, precise drug release, sensing capabilities, and minimally invasive action within a single system. Their capacity to cross the blood–brain barrier, concentrate within tumor tissue, and deliver therapy accurately helps overcome key weaknesses of conventional treatments. Preclinical studies, including enzyme-powered and biohybrid designs, show improved tumor targeting, deeper penetration, and greater therapeutic impact compared to standard nanocarriers. Despite this potential, clinical application requires careful assessment of long-term safety, compatibility with biological systems, large-scale manufacturing feasibility, and appropriate regulatory and ethical frameworks. Continued collaboration across engineering, medical, and computational fields—along with advancements in intelligent control and targeting—will be essential. With these developments, nanorobotic systems could significantly advance early detection and personalized treatment in brain tumor care.
1. Naik MH, Satyanarayana J, Kudari RK. Nanorobots in drug delivery systems and treatment of cancer. Characterization and Application of Nanomaterials. 2024 Aug 28;7(2):2539. 2. Monje M. The neuroscience of brain cancers. Neuron. 2025;113(17):2734–2739. 3. Loushambam B, Shimray, Mirinrinchuiphy MK, Khangembam R, Krishnaswami V, Vijayaraghavalu S. Nanomedicine-based advances in brain cancer treatment—a review. Neuroglia. 2025 Sep;6(3):28. 4. Farmanfarma KK, Mohammadian M, Shahabinia Z, Hassanipour S, Salehiniya H. Brain cancer in the world: an epidemiological review. DOAJ (Directory of Open Access Journals). 2019 Jul 1. 5. Brain neoplasms: practice essentials, pathophysiology, etiology. eMedicine. 2021 Oct 7. 6. Khizar M, Zaib M, Mahato RK. Nanorobots crossing the blood–brain barrier for targeted chemotherapy: the next frontier. Annals of Medicine & Surgery. 2025 Dec 6;88(1):1124–5. 7. Gorrepati N, Quazi F, Sajid A, Avacharmal R. Use of nanorobots in neuro chemotherapy diagnosis in human. 2024 Aug 1 [cited 2025 Apr 17]. Available from: https://ijgis.pubpub.org/pub/rbrf58ef/release/1 8. Shi D, Wang X, Deng Y, Zhou H, Wang Y, Chu PK, et al. Smart micro/nanorobots for drug delivery in the brain. Progress in Materials Science. 2025 Jul 6;155:101533. 9. Aggarwal M, Kumar S. The use of nanorobotics in the treatment therapy of cancer and its future aspects: a review. Cureus. 2022 Sep 20;14(9). 10. Kumar SS. Nanorobots a future device for diagnosis and treatment. Journal of Pharmacy and Pharmaceutics. 2018 Aug 5;5(1):44–9.
Publication Date
9/12/2026
Peer Review Type
Double-Blind Peer Review
Review Rounds: 2
Documents
Article Views
0
Total views since publication
PDF Downloads
4
Total downloads since publication
Geographic Reach
5
Digital Preservation: This article is permanently archived on Zenodo and complies with all data preservation standards across major indexing platforms.
Plagiarism Screening
This manuscript has been checked for plagiarism using TurnitinPlagiarismChecker software.
Conflict of Interest
The authors declare no conflict of interest related to this research work.
Funding Information
No funding information available for this research.
Related research in the same subject area
Loading similar articles...